Tejas Savant
Stock Analyst at Morgan Stanley
(2.42)
# 2,425
Out of 5,182 analysts
245
Total ratings
43.75%
Success rate
-0.85%
Average return
Main Sectors:
Stocks Rated by Tejas Savant
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCYT Veracyte | Maintains: Underweight | $48 → $37 | $31.09 | +19.01% | 16 | Mar 6, 2026 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $24 → $19 | $13.52 | +40.53% | 4 | Mar 6, 2026 | |
| PSNL Personalis | Maintains: Equal-Weight | $11 → $10 | $6.02 | +66.11% | 15 | Mar 5, 2026 | |
| TEM Tempus AI | Maintains: Overweight | $85 → $70 | $42.94 | +63.02% | 7 | Mar 3, 2026 | |
| NTRA Natera | Maintains: Overweight | $265 → $250 | $193.03 | +29.51% | 16 | Mar 3, 2026 | |
| GRAL GRAIL | Maintains: Equal-Weight | $110 → $60 | $45.63 | +31.49% | 4 | Feb 24, 2026 | |
| TMO Thermo Fisher Scientific | Maintains: Overweight | $656 → $670 | $496.11 | +35.05% | 16 | Dec 2, 2025 | |
| IQV IQVIA Holdings | Maintains: Overweight | $250 → $265 | $167.34 | +58.36% | 12 | Dec 2, 2025 | |
| TXG 10x Genomics | Downgrades: Equal-Weight | $17 → $20 | $23.27 | -14.05% | 16 | Dec 2, 2025 | |
| ADPT Adaptive Biotechnologies | Maintains: Equal-Weight | $11 → $16 | $12.79 | +25.10% | 13 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $100 → $105 | $120.93 | -13.17% | 9 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $12 | $7.90 | +51.90% | 20 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $10 → $8 | $7.69 | +4.03% | 14 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $7 | $4.53 | +54.53% | 9 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $7 | $9.67 | -27.61% | 2 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $3.07 | +62.87% | 13 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $32 → $21 | $4.35 | +382.76% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2 | $1.34 | +49.25% | 13 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $40 | $6.45 | +520.16% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $6 | $2.95 | +103.39% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $10 | $4.76 | +110.08% | 8 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.75 | $2.12 | +29.72% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $1.68 | +495.24% | 10 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $73 | $78.60 | -7.12% | 9 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $350 → $250 | $175.65 | +42.33% | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $140 → $100 | $13.13 | +661.61% | 5 | May 12, 2022 |
Veracyte
Mar 6, 2026
Maintains: Underweight
Price Target: $48 → $37
Current: $31.09
Upside: +19.01%
Stevanato Group
Mar 6, 2026
Maintains: Equal-Weight
Price Target: $24 → $19
Current: $13.52
Upside: +40.53%
Personalis
Mar 5, 2026
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $6.02
Upside: +66.11%
Tempus AI
Mar 3, 2026
Maintains: Overweight
Price Target: $85 → $70
Current: $42.94
Upside: +63.02%
Natera
Mar 3, 2026
Maintains: Overweight
Price Target: $265 → $250
Current: $193.03
Upside: +29.51%
GRAIL
Feb 24, 2026
Maintains: Equal-Weight
Price Target: $110 → $60
Current: $45.63
Upside: +31.49%
Thermo Fisher Scientific
Dec 2, 2025
Maintains: Overweight
Price Target: $656 → $670
Current: $496.11
Upside: +35.05%
IQVIA Holdings
Dec 2, 2025
Maintains: Overweight
Price Target: $250 → $265
Current: $167.34
Upside: +58.36%
10x Genomics
Dec 2, 2025
Downgrades: Equal-Weight
Price Target: $17 → $20
Current: $23.27
Upside: -14.05%
Adaptive Biotechnologies
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $11 → $16
Current: $12.79
Upside: +25.10%
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $100 → $105
Current: $120.93
Upside: -13.17%
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $15 → $12
Current: $7.90
Upside: +51.90%
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $10 → $8
Current: $7.69
Upside: +4.03%
May 28, 2025
Maintains: Equal-Weight
Price Target: $9 → $7
Current: $4.53
Upside: +54.53%
May 5, 2025
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $9.67
Upside: -27.61%
Mar 25, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $3.07
Upside: +62.87%
Nov 18, 2024
Maintains: Equal-Weight
Price Target: $32 → $21
Current: $4.35
Upside: +382.76%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $1.34
Upside: +49.25%
May 15, 2024
Maintains: Equal-Weight
Price Target: $80 → $40
Current: $6.45
Upside: +520.16%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $2.95
Upside: +103.39%
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $4.76
Upside: +110.08%
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $2.12
Upside: +29.72%
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $1.68
Upside: +495.24%
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $78.60
Upside: -7.12%
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $175.65
Upside: +42.33%
May 12, 2022
Maintains: Equal-Weight
Price Target: $140 → $100
Current: $13.13
Upside: +661.61%